CompLEEment-1: Updated Results From the Phase IIIb Study of Ribociclib Plus Letrozole in HR+, HER2- Advanced Breast Cancer

Dr. Yara Abdou discusses Ki-67 testing and adjuvant abemaciclib in HR+/HER2-, node-positive, high-risk early breast cancer, from Clinical Care Options (CCO)

Yara Abdou, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: May 12, 2022 Expired: May 11, 2023

Slideset from Dr. Yara Abdou on Ki-67 and adjuvant abemaciclib for HR+/HER2-, node-positive, high-risk EBC, from Clinical Care Options (CCO)

Yara Abdou, MD Released: May 12, 2022

On-demand webcast on HER2, HER3, and TROP2 antibody-drug conjugates in breast, gastrointestinal, and lung cancers, from Clinical Care Options (CCO)

Aditya Bardia, MD, MPH Yelena Y. Janjigian, MD Sandip P. Patel, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits™ Released: May 11, 2022 Expired: May 10, 2023

On-demand Clinical Care Options (CCO) webcast: expert review of data on the optimal utilization of Ki67 testing in HR-positive/HER2-negative early breast cancer

Joyce O'Shaughnessy, MD
Program Director Sara Tolaney, MD, MPH
Program Director Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 11, 2022 Expired: May 10, 2023